Category: 88511-37-9

88511-37-9, 1-(Isoxazol-3-yl)ethanone is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,88511-37-9

Step 2:Pyrazole formation: Dione enolate B was diluted with ethanol and consecutively charged with HCI (e.g., 3 equiv, 1.25 M solution in ethanol) and arylhydrazine hydrate (e.g., 1.15 equiv). The reaction mixture was heated to 70 C and stirred at this temperature until cyclization was deemed complete (e.g., by LC/MS analysis, typically 30 minutes). Once complete, the reaction mixture was treated carefully with solid sodium bicarbonate (e.g., 4 equiv) and diluted with dichloromethane and water. Layers were separated, and aqueous layer was futher diluted with water before extraction with dichloromethane (3x). The combined organics were washed with brine, dried over MgS04, filtered, and concentrated in vacuo. The resulting pyrazole C was then purified by S1O2 chromatography using an appropriate gradient of EtOAc in hexanes.

The synthetic route of 88511-37-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; IRONWOOD PHARMACEUTICALS, INC.; RENNIE, Glen Robert; PERL, Nicholas; LEE, Thomas Wai-Ho; RENHOWE, Paul Allan; NAKAI, Takashi; MERMERIAN, Ara; IM, G-Yoon Jamie; (235 pag.)WO2016/44445; (2016); A2;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.88511-37-9,1-(Isoxazol-3-yl)ethanone,as a common compound, the synthetic route is as follows.,88511-37-9

General procedure: To a solution of ketone A in THF cooled to -78 C, LiHMDS (e.g., 0.9 eq, 1.0 M in toluene) is added dropwise, for example using a syringe. The reaction mixture is then allowed to warm to about 0 C, then charged with diethyl oxalate (1.2 eq). At this time, the reaction mixture is warmed to room temperature and stirred at that temperature until judged complete (e.g., using either TLC or LC/MS analysis). Once the reaction is complete (reaction time typically about 45 minutes), the product dione enolate B is used as-is in Step 2, i.e., the cyclization step, without any further purification

The synthetic route of 88511-37-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; IRONWOOD PHARMACEUTICALS, INC.; IM, G-Yoon, Jamie; IYENGAR, Rajesh; MOORE, Joel; FRETZEN, Angelika; WO2014/47111; (2014); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.88511-37-9,1-(Isoxazol-3-yl)ethanone,as a common compound, the synthetic route is as follows.

88511-37-9, To a -78 C solution of l-(isoxazol-3-yl)ethanone (46 mg, 0.41 mmol) in tetrahydrofuran (1 mL) was added lithium hexamethyldisilazide (1 M in toluene, 370 mu, 0.37 mmol) in a dropwise manner over the course of 5 minutes. The solution was immediately warmed to 0 C for 30 minutes at which point methyl pyrimidine-2-carboxylate (49 mg, 0.35 mmol) was added in a single portion. After stirring for 15 minutes at 0 C, the solution was warmed to room temperature for 18 hours. The solvent was removed in vacuo, and residue was diluted with ether (5 mL) and filtered. The resulting solid (72 mg, 0.32 mmol) was re-suspended in ethanol (0.5 mL) with 3-fluoro-2-(hydrazinylmethyl)pyridine dihydrochloride (60 mg, 0.28 mmol). The solution was heated to 40 C until LCMS indicated consumption of intermediate dione. The solvent was removed in vacuo. The crude residue was purified via silica gel chromatography (3-100% hexanes in ethyl acetate) to give compound 57 (20 mg, 20% yield) as an off-white solid. Compound-57: 1H-NMR (400 MHz, CDC13) delta 8.81 (d, 2H), 8.43 (d, 1H), 8.21 (d, 1H), 7.49 (s, 1H), 7.35 (dt, 1H), 7.21 (t, 1H), 7.12-7.16 (m, 1H), 6.68 (d, 1H), 6.19 (s, 2H).

88511-37-9 1-(Isoxazol-3-yl)ethanone 21349800, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; IRONWOOD PHARMACEUTICALS, INC.; KIM, Charles; NAKAI, Takashi; MOORE, Joel; PERL, Nicholas, Robert; IM, G-yoon, Jamie; BARDEN, Timothy, Claude; IYENGAR, Rajesh, R.; ZIMMER, Daniel, P.; FRETZEN, Angelika; RENHOWE, Paul, Allan; WO2013/101830; (2013); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem